Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma

• Status: Completed
• Trial end date: 2005-01-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug or combining chemotherapy with radiation therapy may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by radiation therapy in treating patients who have surgically resected, newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor, or incompletely resected ependymoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Hospital Los Angeles
• Collaborator: National Cancer Institute (NCI)
• Treatments: Cyclophosphamide; Etoposide; Methotrexate; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Histological confirmation of one of the following:

• High stage medulloblastoma with neuraxis dissemination (Chang stage M1 or greater)

• Primitive neuroectodermal tumor

• Ependymoma

• Incompletely resected on postoperative MRI or neurosurgical report

• Definitive prior surgery within 42 days of study

PATIENT CHARACTERISTICS:

Age:

• 10 to 65

Performance status:

• Not specified

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Bilirubin less than 1.5 mg/dL

• SGPT less than 2.5 times upper limit of normal

Renal:

• Creatinine clearance greater than 60 mL/min

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• No prior chemotherapy

Endocrine therapy:

• Prior corticosteroids allowed

• No concurrent corticosteroids as antiemetics

Radiotherapy:

• No prior radiotherapy

Surgery:

• See Disease Characteristics